UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 22, 2017

BioTelemetry, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		000-55039		46-2568498
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)


1000 Cedar Hollow Road Malvern, PA		19355
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (610) 729-7000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

BioTelemetry, Inc. (the “Company”) Board of Directors promoted Heather Getz, the Company’s Senior Vice President, Chief Financial Officer, to Executive Vice President, Chief Financial Officer.

The Compensation Committee of the Board of Directors of the Company approved a salary increase for Mrs. Getz, effective May 15, 2017, as follows:

Name	Title	Annual Base Salary After Increase
Heather Getz	Executive Vice President, Chief Financial Officer	$	380,000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioTelemetry, Inc.


	By:	/s/ Peter Ferola
		Peter Ferola
		Senior Vice President and General Counsel
Date: May 22, 2017